Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

MA-0217 as a promising new agent for ischemic acute kidney injury

Nov. 27, 2017

New vasopressin receptor antagonists presented by Bayer

Nov. 23, 2017

Ardelyx discontinues development of RDX-7675

Nov. 22, 2017

Calliditas Therapeutics gives update on phase III study plans for Nefecon

Nov. 21, 2017

FDA extends review period for Tlando NDA

Nov. 20, 2017

Bayer discovers new vasopressin receptor antagonists

Nov. 17, 2017

Investigational mineralocorticoid receptor antagonist KBP-5074 evaluated in phase I trial

Nov. 17, 2017

Achillion reports preliminary data from phase II study of ACH-4471 in C3G

Nov. 15, 2017

TP-0469711 demonstrates promising activity as a new therapeutic for hyperphosphatemia

Nov. 14, 2017

Novel antibody against TGF-beta1 shows efficacy without cardiotoxicity in fibrosis model

Nov. 14, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...